Blood-Brain Barrier in Alzheimer's: New Insights Reveal Promising Treatment Targets

What Does the Blood-Brain Barrier Reveal About Alzheimer's Disease?

Recent transcriptomic studies have unveiled critical insights into brain endothelial cell (BEC) heterogeneity in Alzheimer's disease (AD), highlighting the blood-brain barrier (BBB) as a potential therapeutic target that has been largely overlooked in conventional AD research. A comprehensive analysis of single-cell and single-nucleus RNA sequencing data from multiple studies reveals that BECs, particularly capillary endothelial cells (capECs), undergo significant transcriptomic changes during AD progression, with distinct patterns emerging across different brain regions and disease stages.

The BBB plays a fundamental role in maintaining central nervous system homeostasis, and its impairment occurs early in AD pathogenesis, preceding both neuronal pathologies and cognitive decline. While current therapeutic approaches like Lecanemab have shown promise in targeting amyloid-β (Aβ) clearance, they face challenges including amyloid-related imaging abnormalities (ARIA) and infusion reactions. These limitations underscore the need for alternative therapeutic strategies, with BBB protection representing an underexplored avenue that could significantly enhance Aβ clearance and improve cognitive function. Advanced transcriptomic techniques including single-cell RNA sequencing (scRNA-seq), single-nuclear RNA sequencing (snRNA-seq), and vessel isolation and nuclei extraction for sequencing (VINE-seq) have provided unprecedented insights into the cellular composition and functional changes in the cerebral vasculature during AD progression.

Could Brain Endothelial Subtypes Dictate Regional Vulnerability?

Studies examining brain tissues from AD patients and cognitively normal controls have identified distinct endothelial subtypes along the arteriovenous axis: arterial endothelial cells (aECs), capillary endothelial cells (capECs), and venule endothelial cells (vECs). Each subtype exhibits specialized functions and gene expression patterns, with capECs comprising approximately 80% of BECs and displaying the most prominent BBB characteristics, including tight junctions and specialized transport systems. Importantly, the relative proportions of these endothelial subtypes vary significantly across brain regions, with vulnerable areas like the entorhinal cortex (EC) and hippocampus (HC) showing lower capEC abundance compared to other regions such as the prefrontal cortex and visual cortex. This regional variation may contribute to the differential vulnerability of brain regions to AD pathology.

How Do Microvascular Architectures Affect Function?

The cerebral vascular system consists of a hierarchy of blood vessels, including arteries or arterioles (10–100 μm), capillaries (4–10 μm), and venules (10–50 μm). Recent studies using immunolabeling and tissue clearing techniques have revealed distinct regional variations in microvascular architecture. The gray matter has a higher density of microvessels compared to the white matter, with different orientations of blood vessels in each area. Gray matter vessels are shorter and arranged perpendicularly to cortical layers, while white matter vessels are longer and parallel to axonal fibers. These structural differences are accompanied by variations in junctional protein composition and endothelial barrier function, with higher expression of tight junction proteins like occludin and claudin-5 in white matter compared to gray matter.

What Genetic Factors Influence BBB Dysfunction in AD?

Genome-wide association studies (GWAS) have identified numerous AD risk genes that are highly expressed in BECs, including PICALM, CD2AP, PLCG2, and INPP5D. These genes are involved in critical BBB functions such as clathrin-mediated transcytosis, Aβ clearance, neuroimmune responses, and angiogenesis regulation. Transcriptomic analyses have further revealed differentially expressed genes related to AD (adDEGs) in BECs, with capECs exhibiting the highest number of adDEGs. These altered gene expressions are associated with BBB maintenance, angiogenesis, inflammation, endothelial activation, cytokine production, and apoptotic signaling. The identification of upstream regulators of these adDEGs has provided insights into the drivers of dysfunctional gene programs in AD, highlighting pathways related to cellular migration, extracellular matrix organization, glucose homeostasis, and immune responses.

Could Amyloid-β Drive Endothelial Transcriptomic Shifts?

One of the most significant findings is that Aβ burden exerts the greatest impact on BEC transcriptomic patterns compared to tau burden and APOE4 genotype. Different forms of Aβ burden, including diffuse plaques, neuritic plaques, and cerebral amyloid angiopathy (CAA), induce distinct transcriptomic alterations in BECs. For instance, diffuse and neuritic plaques primarily upregulate genes involved in inflammatory processes and metabolism, while CAA affects genes related to cell adhesion, lipid metabolism, and BBB transport systems. Furthermore, BECs exhibit six distinct transcriptomic patterns linked to disease stages, reflecting adaptive responses to insufficient energy supply and cellular stress as the disease progresses. These patterns include progressive downregulation of genes related to ion transport and TGFβ signaling, progressive upregulation of genes associated with cellular stress responses and apoptotic processes, and more complex patterns showing initial changes followed by stabilization or return to baseline.

How Does Endothelial Activation Shape AD Pathology?

The concept of an activated phenotype of endothelial cells under disease conditions differs significantly from the constitutive phenotype observed in normal conditions. Activated endothelial cells exhibit proinflammatory and invasive profiles, characterized by overproduction of cytokines and adhesion molecules such as E-selectin, P-selectin, ICAM-1, and VCAM-1, along with related immune cell infiltration. They also acquire angiogenic properties and upregulate various stress-related genes associated with ischemia, hypoxia, and acidosis. In AD brains, there is a significant decrease in Hoechst+ nuclei within collagen IV+ vessels, indicating "string vessels" or "capillary regression" – thin strands of connective tissue that are remnants of capillaries resulting from inflammation-induced apoptosis.

What Are the Consequences of Impaired NVU Communication?

The transcriptomic studies have also revealed dysregulated communications among cells in the neurovascular unit (NVU) in AD. The analysis of interacting "gene pairs" has provided insights into how other brain cells influence BECs, with pairs such as ADAM10/NOTCH1, APOE/SCARB1, and TGFB2/TGFBR2 linked to BBB disruptions. These findings highlight the importance of cell-cell communication within the NVU and suggest that disruptions in these interactions contribute to early BBB dysfunction in AD. The regional specialization of endothelial functions observed in healthy brains is lost in AD, with vulnerable areas showing reduced expression of genes related to homeostatic processes such as BBB maintenance and vascular permeability. This loss of regional specialization, combined with the lower abundance of capECs in vulnerable regions, may contribute to the selective vulnerability of certain brain areas to AD pathology.

Maintaining BBB function and integrity requires constant communication and coordination among the cells in the NVU, including BECs, pericytes, astrocytes, neurons, microglia, and oligodendrocytes. Single-cell transcriptomic studies have mapped the cell-cell communication within the NVU, showing that the most frequent communications occur between capECs/pericytes and astrocytes/excitatory neurons in specific directional manners. Signaling from capECs to astrocytes, capECs to neurons, and pericytes to neurons are very common, while signaling from neurons to capECs is less common. The data indicate that signaling from capECs and pericytes to neurons and astrocytes is associated with neuronal and glial proliferation, glucose and lipid metabolism, and enhanced immune responses, which aligns with the observed glial hypertrophy in AD. Meanwhile, signaling from neurons and glial cells is linked to the disruption of BBB integrity, including the downregulation of genes related to collagen, laminin, and extracellular matrix proteins.

Can Endothelial Signatures Inform Future Therapeutic Strategies?

These transcriptomic insights have significant implications for AD research and therapeutic development. They suggest that early endothelial activation, pathological angiogenesis, and inflammatory responses lead to distinct transcriptomic and phenotypic signatures in AD. Consistent with these findings, endothelial-specific adhesion molecules such as ICAM-1, VCAM-1, and selectins are upregulated in AD patients, facilitating leukocyte infiltration and exacerbating neuroinflammation. In meningeal and cortical blood vessels, and even in the brain parenchyma of AD patients, neutrophils have been detected by increased immunoreactivity to the neutrophil-specific marker Cathepsin G. Macrophages and CD4+ and CD8+ T cells have also been observed in AD brain tissues, further indicating compromised BBB integrity and increased immune cell infiltration.

Do Genetic Risk Factors Exacerbate BBB Disruption?

The cell-cell communication analysis also provides evidence of the association between APOE4, the strongest genetic risk factor for sporadic AD, and BEC disruptions. APOE4 is predominantly expressed in microglia and astrocytes in AD and potentially impacts the integrity of the BBB and the clearance of Aβ via the interaction of astrocytic endfeet with blood vessels. It may also be a key driver of the ARIA phenomenon observed in anti-amyloid antibody trials, which reflects underlying microvascular changes associated with inflammatory responses that may be exacerbated by the removal of amyloid from amyloid-laden vessels.

Could a Multicellular Approach Revolutionize AD Treatment?

To enhance future drug development strategies for AD, it is essential to consider multicellular-level and region-specific approaches, taking into account the vulnerability of specific regions and the vascular components of AD pathology. The NVU is a highly coordinated system centered around the BBB, comprising various cell types including pericytes and mural cells. Future research should focus on developing strategies to protect BBB integrity, modulate cell-cell communications within the NVU, and address the regional vulnerabilities observed in AD. Could targeting the BBB and endothelial dysfunction represent a paradigm shift in AD therapeutic development? How might a combination approach addressing both neuronal and vascular aspects of AD pathology enhance treatment efficacy? What regulatory challenges might arise in implementing therapies targeting the BBB, and how can these be addressed to accelerate clinical translation? These questions warrant further investigation as the field continues to evolve toward more comprehensive and effective treatments for this devastating neurodegenerative disorder.

Summary

This comprehensive analysis explores groundbreaking discoveries about the blood-brain barrier's role in Alzheimer's disease (AD). Research using advanced transcriptomic techniques has revealed significant changes in brain endothelial cells during AD progression, particularly in capillary endothelial cells. The studies highlight regional variations in microvascular architecture and endothelial subtypes that may influence disease vulnerability. Key findings include the impact of amyloid-β on endothelial transcriptomic patterns, the role of genetic factors in BBB dysfunction, and the importance of cell-cell communication within the neurovascular unit. These insights suggest that targeting BBB protection could represent a promising new direction for AD treatment, potentially complementing existing therapeutic approaches.